TY - JOUR T1 - Antibody Response after First-dose of ChAdOx1-nCOV (Covishield™<sup>®</sup>) and BBV-152 (Covaxin™<sup>®</sup>) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study JF - medRxiv DO - 10.1101/2021.04.07.21255078 SP - 2021.04.07.21255078 AU - Awadhesh Kumar Singh AU - Sanjeev Ratnakar Phatak AU - Nagendra Kumar Singh AU - Arvind Gupta AU - Arvind Sharma AU - Kingshuk Bhattacharjee AU - Ritu Singh Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/13/2021.04.07.21255078.abstract N2 - Background Two vaccines are currently being administered in India to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the humoral immune response after the first dose of two vaccines ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) in Indian health care workers (HCW).Methods This ongoing, Pan-India, Cross-sectional, Coronavirus Vaccine-induced Antibody Titre (COVAT) study is being conducted amongst HCW, with or without past history of SARS-CoV-2 infection. SARS-CoV-2 anti-spike binding antibody is being assessed quantitatively at four timepoints between 21 days or more after the first dose to 6 months after the second dose. Primary aim is to analyze antibody response following each dose of both vaccines and its correlation to age, sex, body mass index (BMI) and comorbidities. Here we report the preliminary results of anti-spike antibody response after the first dose.Results Amongst the 552 HCW (325 Male, 227 Female), 456 and 96 received first dose of Covishield and Covaxin respectively. Overall, 79.3% showed seropositivity after the first dose. Responder rate and median (IQR) rise in anti-spike antibody was significantly higher in Covishield vs. Covaxin recipient (86.8 vs. 43.8%; 61.5 vs. 6 AU/ml; both p&lt;0.001). This difference persisted in propensity-matched (age, sex and BMI) analysis in 172 subjects. No difference was observed with age, gender and BMI. History of hypertension had lower responder rate (65.7 vs. 82.3%, p=0.001). Covishield recipient had more adverse event vs. Covaxin arm (46.7 vs. 31.2%, p=0.006). Presence of comorbidities, past SARS-CoV-2 infection and vaccine types used were independent predictors for seropositivity after the first dose, in multiple logistic regression analysis.Conclusions While both vaccines elicited immune response, seropositivity rates to anti-spike antibody were significantly higher in Covishield recipient compared to Covaxin after the first dose. Ongoing COVAT study will further enlighten the immune response between two vaccines after the second dose.HighlightsThis study evaluated the humoral antibody response of two SARS-CoV-2 vaccines Covishield™ and Covaxin™ in Indian health-care workers.Both vaccines showed seropositivity to anti-spike antibody, 21 days or more after the first dose.Responder rates were higher in Covishield recipient compared to Covaxin in propensity-matched cohorts.Past SARS-CoV-2 infection, presence of comorbidities and vaccine type received were independent predictors of antibody response after the first dose.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This cross-sectional study that was approved by the ethical committee of Thakershy Charitable Trust, Ahmedabad, Gujrat, India.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the authors are responsible for the originality of this study. Original data can be shared from first author if necessary, after a reasonable request. ER -